MARKET

ATNM

ATNM

ACTINIUM PHARMAC
AMEX

Real-time Quotes | Nasdaq Last Sale

11.47
+0.19
+1.68%
After Hours: 11.21 -0.26 -2.27% 17:07 10/26 EDT
OPEN
11.35
PREV CLOSE
11.28
HIGH
11.52
LOW
11.10
VOLUME
281.16K
TURNOVER
--
52 WEEK HIGH
19.47
52 WEEK LOW
4.710
MARKET CAP
155.84M
P/E (TTM)
-0.1112
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Actinium Pharma cheers National Institutes of Health grant to study novel Iomab-ACT
National Institutes of Health awarded Actinium Pharmaceuticals (ATNM) +6% PM, a Small Business Technology Transfer grant to support a clinical collaboration with Memorial Sloan Kettering ((MSK)) Cancer Center to study Iomab-ACT, Actinium's
Seekingalpha · 5d ago
The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20)
Benzinga · 5d ago
Actinium Pharma Wins Grant By National Institutes Of Health To Study Novel Iomab-ACT Targeted Conditioning With CD19 CAR T-Cell Therapy, No Terms Disclosed
Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium" or the "Company") today announced that the National Institutes of Health has awarded Actinium a Small Business Technology Transfer grant to
Benzinga · 5d ago
Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that the National Institutes of Health has awarded Actinium a Small Business Technology Transfer grant to support a clinical collaboration with Memorial Sloan Kettering Cancer Center ("MSK") to study Iomab-ACT, Actinium's CD45-targeting Antibody Radio-Conjugate, for targeted conditioning to achieve lymphodepletion prior to administration of a CD19-targeted CAR T-cell therapy developed at MSK. The CD19 CAR-T has been previously studied by MSK in a Phase 2 trial with chemotherapy conditioning in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) or diffuse large B-cell lymphoma (DLBCL). MSK will lead this first of its kind study to utilize targeted radiopharmaceutical ARC-based lymphodepletion to replace chemotherapy-based conditioning prior to CAR T-cell therapy. The study will assess the feasibility of using Iomab-ACT targeted lymphodepletion prior to MSK's 19-28z CAR-T and assess safety and efficacy outcomes relative to results with MSK's CAR-T 19-28z in patients who had received chemotherapy-based lymphodepletion prior to CAR-T administration.
PR Newswire · 5d ago
Actinium Pharmaceuticals expands R&D capabilities with new research facility in New York City
Actinium Pharmaceuticals ([[ATNM]] +0.9%) announces the launch of its new research and development lab facility in New York City."Our new research facility will allow us to significantly accelerate our preclinical
Seekingalpha · 10/14 14:10
Actinium Pharmaceuticals Announces The Launch Of New Research & Development Lab Facility In New York
Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium" or the "Company") today announced the launch of its new research and development lab facility in New York City.  This new research
Benzinga · 10/14 11:06
Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the launch of its new research and development lab facility in New York City. This new research facility expands Actinium's internal R&D capabilities and will be focused on developing novel Antibody Radiation Conjugate (ARC) candidates, ARC therapeutic combination strategies, and supporting AWE platform research collaborations. Actinium's R&D efforts will employ a multidisciplinary approach leveraging its team's expertise and experience in cancer cell biology, radiochemistry, radiation sciences, immunology and oncology drug development. The proprietary AWE technology platform, protected by over one hundred and twenty-five patents, is the foundation for Actinium's R&D and exploits multiple different radioisotope payloads including the potent alpha-emitter, Actinium-225.
PR Newswire · 10/14 11:00
We Think Actinium Pharmaceuticals (NYSEMKT:ATNM) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 10/09 11:37
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATNM. Analyze the recent business situations of ACTINIUM PHARMAC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATNM stock price target is 43.33 with a high estimate of 65.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 42
Institutional Holdings: 23.40M
% Owned: 172.20%
Shares Outstanding: 13.59M
TypeInstitutionsShares
Increased
10
5.54M
New
5
10.91M
Decreased
6
1.59M
Sold Out
5
306.41K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.80%
Pharmaceuticals & Medical Research
-1.00%
Key Executives
Chairman/Chief Executive Officer/Director
Sandesh Seth
Chief Financial Officer/Chief Accounting Officer
Steve O'Loughlin
Chief Scientific Officer
Dale Ludwig
Other
Mark Berger
Vice President
Robert Daly
Lead Director/Independent Director
C. David Nicholson
Vice President
Steven Price
Independent Director
Jeffrey Chell
Independent Director
Ajit Shetty
Vice President
Vijay Reddy
Independent Director
Richard Steinhart
Vice President
Jehan Rowlands
Independent Director
C.David Nicholson
Independent Director
C. Nicholson
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ATNM
Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Actinium Pharmaceuticals Inc stock information, including AMEX:ATNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATNM stock methods without spending real money on the virtual paper trading platform.